
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans.
Click here for full Story http://www.medicalnewstoday.com/articles/107819.php |